Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F14%3A10282883" target="_blank" >RIV/00179906:_____/14:10282883 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/60162694:G44__/14:43875087 RIV/00216208:11150/14:10282883
Výsledek na webu
<a href="http://dx.doi.org/10.5152/akd.2013.4803" target="_blank" >http://dx.doi.org/10.5152/akd.2013.4803</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5152/akd.2013.4803" target="_blank" >10.5152/akd.2013.4803</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome
Popis výsledku v původním jazyce
Acetylsalicylic acid and ADP inhibitor-based therapy is well established in coronary artery disease treatment. Despite this treatment, platelet reactivity may remain high in some patients. Identification of risk factors associated with high on-treatmentplatelet reactivity is essential for rational antiplatelet treatment monitoring and for tailored antiplatelet treatment. The aim of the study was to assess the relationship between mean platelet volume, platelet count, platelet hematocrit and high on-treatment platelet reactivity in patients with acute coronary syndrome treated using percutaneous coronary intervention and its association with long-term mortality. A cohort of 190 patients with acute myocardial infarction treated with acetylsalicylic acidand clopidogrel was enrolled in the study. We documented increased mean platelet volume, platelet count and platelet hematocrit in patients with high on-treatment platelet reactivity. Mean platelet volume and platelet count were document
Název v anglickém jazyce
Mean platelet volume and platelet count: overlooked markers of high on-treatment platelet reactivity and worse outcome in patients with acute coronary syndrome
Popis výsledku anglicky
Acetylsalicylic acid and ADP inhibitor-based therapy is well established in coronary artery disease treatment. Despite this treatment, platelet reactivity may remain high in some patients. Identification of risk factors associated with high on-treatmentplatelet reactivity is essential for rational antiplatelet treatment monitoring and for tailored antiplatelet treatment. The aim of the study was to assess the relationship between mean platelet volume, platelet count, platelet hematocrit and high on-treatment platelet reactivity in patients with acute coronary syndrome treated using percutaneous coronary intervention and its association with long-term mortality. A cohort of 190 patients with acute myocardial infarction treated with acetylsalicylic acidand clopidogrel was enrolled in the study. We documented increased mean platelet volume, platelet count and platelet hematocrit in patients with high on-treatment platelet reactivity. Mean platelet volume and platelet count were document
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/NR9174" target="_blank" >NR9174: Stanovení a význam rezistence na protidestičkovou léčbu</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Anadolu Kardiyoloji Dergisi
ISSN
1302-8723
e-ISSN
—
Svazek periodika
14
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
TR - Turecká republika
Počet stran výsledku
2
Strana od-do
85-86
Kód UT WoS článku
000338105200019
EID výsledku v databázi Scopus
—